If you have been reading about nitric oxide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
== Modern-day Cossack identity == Ethnic, or "born" (prirodnye), Cossacks are those who can trace, or claim to trace, their ancestry to people and families identified as Cossack in the Tsarist era. They tend to be Christian, practicing as Orthodox Christians or Old Believers; though there are growing numbers of Rodnovers, especially among Ukrainian Cossacks. Others may be initiated as Cossacks, particularly men in military service. Such initiates may be neither ethnic Slavs, nor Christian. Not all agree that such initiates should be considered Cossack. There is no consensus on an initiation rite or rules. In other cases, individuals may wear Cossack uniform and pass themselves off as Cossack, perhaps because there is a large ethnic Cossack population in the area and the person wants to fit in. Others adopt Cossack clothing in an attempt to take on some of their mythic status. Ethnic Cossacks refer to the re-enactors as ryazhenye (ряженые, or "dressed up phonies"). Because of the lack of consensus on how to define Cossacks, accurate numbers are not available. According to the Russian Census of 2010, 67,573 people identify as ethnic Cossack in Russia. Between 3.5 and 5 million people associate themselves with the Cossack identity in Europe and across the world.
Breeding crops resistant, or at least less susceptible, to pest attacks. Releasing predators, parasitoids, or pathogens to control pest populations as a form of biological control. Chemical control like releasing pheromones into the field to confuse the insects into not being able to find mates and reproduce. Integrated Pest Management: using multiple techniques in tandem to achieve optimal results. Push-pull technique: intercropping with a "push" crop that repels the pest, and planting a "pull" crop on the boundary that attracts and traps it.
== Changes for 2020 exam == The Central Board of Secondary Education (CBSE) has been conducting two separate Mathematics examinations in the class 10 board examination, starting from the 2020 session. Mathematics exam till 2019 was Mathematics (Standard), and an easier version, Mathematics (Basic), has been introduced. The option to choose mathematics is available on the registration form for the Class 10 CBSE board examination. Candidates are required to select their test choice while filling out the registration form for the CBSE Class 10 board examination 2020. Minister of Education, MoE (previously Minister of Human Resource Department, HRD), amid the coronavirus outbreak had ordered rescheduling of pending examinations. The exams rescheduled were to be conducted between 1 and 15 July. On 26 June, CBSE released as circular which cancelled the remaining exams and give scores based on the scores of the exams already taken by students. Some students of Delhi who were able to provide three or fewer exams were scored as per their performance in internal exams. This decision came after a judicial ruling.
Sources: en.wikipedia.org
== History == Cellulose was discovered in 1838 by the French chemist Anselme Payen, who isolated it from plant matter and determined its chemical formula. Cellulose was used to produce the first successful thermoplastic polymer, celluloid, by Hyatt Manufacturing Company in 1870. Production of rayon ("artificial silk") from cellulose began in the 1890s and cellophane was invented in 1912. Hermann Staudinger determined the polymer structure of cellulose in 1920. The compound was first chemically synthesized (without the use of any biologically derived enzymes) in 1992, by Kobayashi and Shoda.
Similar employee protections enforced through OSHA are included in the Surface Transportation Assistance Act (1982) to protect truck drivers, the Pipeline Safety Improvement Act (PSIA) of 2002, the Wendell H. Ford Aviation Investment and Reform Act for the 21st Century (AIR 21), and the Sarbanes–Oxley Act, enacted on July 30, 2002 (for corporate fraud whistleblowers). More recent laws with some whistleblower protection include the Patient Protection and Affordable Care Act (ACA), Consumer Product Safety Improvement Act (CPSIA), Seamans Protection Act as amended by the Coast Guard Authorization Act of 2010 (SPA), Consumer Financial Protection Act (CFPA), FDA Food Safety Modernization Act (FSMA), Moving Ahead for Progress in the 21st Century Act (MAP-21), and Taxpayer First Act (TFA). Investigation of retaliation against whistleblowers under 23 federal statutes falls under the jurisdiction of the Directorate of Whistleblower Protection Program (DWPP) of the United States Department of Labor's Occupational Safety and Health Administration (OSHA). New whistleblower statutes enacted by Congress, which are to be enforced by the Secretary of Labor, are generally delegated by a Secretary's Order to the DWPP. The patchwork of laws means that victims of retaliation need to be aware of the laws at issue to determine the deadlines and means for making proper complaints. Some deadlines are as short as 10 days (Arizona State Employees have 10 days to file a "Prohibited Personnel Practice" Complaint before the Arizona State Personnel Board), while others are up to 300 days.
Natural tantalum (73Ta) consists of two isotopes: observationally stable 181Ta (99.988%) and 180mTa (0.012%). There are also 35 known artificial radioisotopes, the longest-lived of which are 179Ta with a half-life of 1.82 years, 182Ta with a half-life of 114.74 days, 183Ta with a half-life of 5.1 days, and 177Ta with a half-life of 56.46 hours. All other isotopes have half-lives under a day, most under an hour. There are also numerous isomers, the most stable of which (other than 180mTa) is 182m2Ta with a half-life of 15.8 minutes. All isotopes and nuclear isomers of tantalum are either radioactive or observationally stable, meaning that they are predicted to be radioactive but no actual decay has been observed. Tantalum has been proposed as a "salting" material for nuclear weapons (cobalt is another, better-known salting material). A jacket of tantalum, irradiated by the intense high-energy neutron flux of the weapon, would be transmuted into the radioactive isotope 182Ta, producing about 1.12 MeV of gamma radiation per decay and significantly increasing the radioactivity of the weapon's fallout for months. Such a weapon is not known to have ever been built, tested, or used.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.